ATIC

04/06/2026

Tzield is approved for use in Australia for people with stage 2 type 1 diabetes.
But how do you find out if you have stage 2 type 1 diabetes?
The first step is to find out if you have type 1 diabetes related autoantibodies. These autoantibodies can be detected on a simple screening blood test. offers free autoantibody screening to all people in Australia who have a family member with type 1 diabetes and areover 2 years old. The test is simple and can be done in the comfort of your own home. For more information, visit their website at https://type1screen.org.

01/06/2026

Following the approval of Tzield in Australia last week, we received a lot of questions about the stages of T1D. Our friends at Breakthrough T1D Australia have produced this wonderful image that explains the stages in detail. They also have more information available on their website at https://breakthrought1d.org.au/early-detection-of-type-1-diabetes/stages/

28/05/2026

Do you have type 1 diabetes?
Are you keen to participate in research that may help to stop or reduce the immune system attack on the pancreas?
You can find out more about this clinical trial on our website at https://atic.svi.edu.au/clinical-trials/clinical-trials/ or reach out to our friendly team on [email protected]

28/05/2026

It was fantastic to feel the excitement about the approval of Tzield for use in Australia yesterday!
For many people, this was the first time they’ve heard the term “immunotherapy” in relation to type 1 diabetes. So, what does it actually mean?
At ATIC, we’ve created a short video explaining:
• what immunotherapy is,
• how it works in type 1 diabetes,
• the stages of type 1 diabetes,
• and how research is changing the future of care
Watch the video here: https://atic.svi.edu.au/news-events/new-video-resource/
This approval marks an exciting new era moving from managing type 1 diabetes to potentially delaying disease progression itself.

ATIC is supported by Breakthrough T1D Australia
Animation by Diabetes UK

The ATIC Community Engagement Panel has led the development of a new video resource designed to raise awareness among health professionals and the community about the benefits of immunotherapy for type 1 diabetes.

27/05/2026

ATIC's own Prof John Wentworth spoke to Channel 9's Sarah Abo on Today this morning about the TGA approval of Tzield. You can share John's excitement here: https://youtu.be/jmW7nqkOxh8?si=WM6vXDQde1Gph2C8

There's new hope this morning for diabetes patients, with a life-ch...

27/05/2026

Sanofi share its wonderful news about Tzield approval in Australia. This post includes the link to the Consumer Medicine Information which includes more information about Tzield, its uses and important safety considerations.

A new therapy, Tzield® (teplizumab) is now registered in Australia for those with an early, pre-symptomatic stage of .

This immunotherapy is indicated to delay the onset of Stage 3 type 1 diabetes mellitus (T1D) in adult and paediatric patients aged 8 years and older with Stage 2 type 1 diabetes mellitus.

Tzield® (teplizumab) is not yet available on the PBS.

All medicines have side effects. The most frequently observed adverse events in patients receiving Tzield® include reductions in certain white blood cells and rash. Bacterial and viral infections, including cases of viral reactivation have been reported with Tzield®.

For more information about the medicine, including additional safety considerations, please see the Consumer Medicine Information > http://spkl.io/618876JOY

27/05/2026

More information from Breakthrough T1D Australia on this game-changing approval of Tzield...

Fantastic type 1 diabetes (T1D) news in Australia this morning: Tzield has been approved by the Therapeutic Goods Administration (TGA) for use in people aged 8+ years who are in stage 2 T1D!

Here’s why it’s so exciting:

🧪 Tzield (teplizumab) can delay the progression of T1D from stage 2 (before people start showing T1D symptoms) to stage 3 (when symptoms of T1D begin and people start needing insulin therapy).

☺️ On average, Tzield means an extra 2 years of life without insulin. That's an extra 2 years without the physical, emotional, financial and mental burdens of T1D.

💉 This is the first new drug approved for T1D in over 100 years, since the discovery of insulin!

🩸 People can only be found in the early stages of T1D through screening. That’s why Breakthrough T1D has been funding early detection and screening initiatives in Australia for many years and is a global leader in the field.

💰 Breakthrough T1D has funded the development of teplizumab for almost 4 decades, from the early discovery research to the landmark clinical trials that proved it could delay T1D progression.

🔓 Next up, Breakthrough T1D will be advocating for the therapy to be listed on the Pharmaceutical Benefits Scheme (PBS), so it can become subsidised and available for all people with stage 2 T1D who want to access it.

We'll share more about Tzield and what this means in the days to come – you can also click the link in the comments to learn more about this exciting news!

26/05/2026

ATIC are delighted to hear the news that Tzield (Teplizumab) has been approved for use in Australia in early stage type 1 diabetes.
Tzield is the first new therapy approved for type 1 diabetes since insulin was discovered over 100 years ago and its approval represents a landmark change in the way that type 1 diabetes is treated.
Tzield reduces the immune system attack on the insulin making cells of the pancreas to allow people to continue to make their own insulin and delaying the need for insulin treatment and the physical and emotional challenges of living with type 1 diabetes.
This is a very exciting day in the treatment of type 1 diabetes in Australia! For more information on this wonderful news, click on the image below.
https://atic.svi.edu.au/news-events/tzield-teplizumab-set-to-transform-type-1-diabetes-care-in-australia/?highlight=tzield

ATIC is supported by Breakthrough T1D Australia

The approval of Tzield® (teplizumab) by the Therapeutic Goods Administration (TGA) marks the first therapy available to delay the onset of clinical type 1 diabetes.

25/05/2026

Reminder: Beyond Insulin (our free seminar series) is happening this Thursday!
We are delighted to have Prof John Wentworth presenting the results of a recent clinical trial on the effects of abatacept and intranasal insulin on type 1 diabetes. To register, please click on the link below:

Seminar 31, Beyond Insulin Seminar Series - ATIC Lead Investigator, Professor John Wentworth presents findings from the Insulin and Abatacept (IAA) trial.

21/05/2026

Reminder that this event is happening next week. Register now!

Join us on Tuesday 26 May for a summit on type 1 diabetes (T1D) early detection programs and emerging immunotherapies.